{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:08:07Z","timestamp":1788808087770,"version":"build-2803163510"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"University of Virginia Comprehensive Cancer Center National Cancer Institute Support","award":["P30CA44579"],"award-info":[{"award-number":["P30CA44579"]}]},{"name":"Farrow-Weiss Endowment Fund"},{"name":"University of Virginia Department of Medicine Physicians Scientist Training"},{"name":"The Population Health and Cancer Outcomes Core at the University of Virginia Comprehensive Cancer Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recently, sodium\u2013glucose cotransporter-2 inhibitors (SGLT2i) have emerged as a treatment option for type 2 diabetes mellitus (T2DM) and have also shown promising anti-tumor activity in preclinical models. Limited clinical data exist regarding the use of SGLT2i in patients with metastatic solid tumor malignancies treated with immune checkpoint inhibitors (ICIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A retrospective, multi-center, matched cohort analysis of patients with a diagnosis of either T2DM and\/or congestive heart failure and an advanced solid tumor malignancy treated with ICIs was performed using the Epic Cosmos database. Ten different solid tumor types, 11 ICIs, and 3 SGLT2i were analyzed. Patients in the exposure group also received an SGLT2i and had at least 1 overlapping cycle with ICI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 1146 patients included, 573 patients received SGLT2i\u2009+\u2009ICIs and 573 received ICIs alone. Compared to patients treated with ICIs, individuals who received SGLT2i\u2009+\u2009ICIs had improved median overall survival (mOS) (27.4 vs 17.4\u2009months, hazard ratio 0.68, log-rank test, P\u2009&amp;lt;\u2009.001). When stratified by histology, significant improvements in mOS were seen for non-small-cell lung cancer and renal cell carcinoma patients. Survival benefit was attenuated when accounting for immortal time bias in late initiators of SGLT2i, though persisted among patients prescribed SGLT2i at or prior to initiation of ICI. Patients in the exposure group experienced longer time on immunotherapy compared to the control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients prescribed SGLT2i at or prior to ICI initiation had a modest improvement in survival compared to patients treated with ICIs alone. SGLT2i may be a beneficial adjunctive therapy in patients treated with ICI, though further studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag298","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:51:00Z","timestamp":1786189860000},"source":"Crossref","is-referenced-by-count":0,"title":["Association of sodium-glucose co-transport protein 2 inhibitor use with clinical outcomes in patients receiving immune checkpoint inhibitors: a pan-tumor propensity-matched analysis"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6076-7084","authenticated-orcid":false,"given":"Sean C","family":"Dougherty","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Virginia Cancer Center , Charlottesville, VA 22908,","place":["United States"]},{"name":"University of Virginia Comprehensive Cancer Center , Charlottesville, VA 22908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Young","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Virginia Cancer Center , Charlottesville, VA 22908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Picon","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Virginia Cancer Center , Charlottesville, VA 22908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"He","sequence":"additional","affiliation":[{"name":"University of Virginia Comprehensive Cancer Center , Charlottesville, VA 22908,","place":["United States"]},{"name":"Department of Public Health Sciences, University of Virginia School of Medicine , Charlottesville, VA 22908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asal","family":"Pilehvari","sequence":"additional","affiliation":[{"name":"University of Virginia Comprehensive Cancer Center , Charlottesville, VA 22908,","place":["United States"]},{"name":"Department of Public Health Sciences, University of Virginia School of Medicine , Charlottesville, VA 22908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3240-6526","authenticated-orcid":false,"given":"Wen","family":"You","sequence":"additional","affiliation":[{"name":"University of Virginia Comprehensive Cancer Center , Charlottesville, VA 22908,","place":["United States"]},{"name":"Department of Public Health Sciences, University of Virginia School of Medicine , Charlottesville, VA 22908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D","family":"Hall","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Virginia Cancer Center , Charlottesville, VA 22908,","place":["United States"]},{"name":"University of Virginia Comprehensive Cancer Center , Charlottesville, VA 22908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4725-0459","authenticated-orcid":false,"given":"Matthew J","family":"Reilley","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Virginia Cancer Center , Charlottesville, VA 22908,","place":["United States"]},{"name":"University of Virginia Comprehensive Cancer Center , Charlottesville, VA 22908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"2026090714312753800_oyag298-B1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B2","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/CCO.0000000000000610","article-title":"Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting","volume":"32","author":"Herrscher","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"2026090714312753800_oyag298-B4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"2026090714312753800_oyag298-B5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2026090714312753800_oyag298-B6","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026090714312753800_oyag298-B7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","article-title":"The tumor microenvironment in the response to immune checkpoint blockade therapies","volume":"11","author":"Petitprez","year":"2020","journal-title":"Front Immunol"},{"key":"2026090714312753800_oyag298-B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026090714312753800_oyag298-B9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Tan","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026090714312753800_oyag298-B10","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1056\/NEJMc1714339","article-title":"Nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B12","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B14","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B17","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B18","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B20","doi-asserted-by":"publisher","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026090714312753800_oyag298-B21","doi-asserted-by":"publisher","first-page":"e223461","DOI":"10.1001\/jamanetworkopen.2022.3461","article-title":"Immune-related adverse events after immune checkpoint inhibitors for melanoma among older adults","volume":"5","author":"Schonfeld","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026090714312753800_oyag298-B22","doi-asserted-by":"publisher","first-page":"e2311181","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy","volume":"6","author":"Aggarwal","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026090714312753800_oyag298-B23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"2026090714312753800_oyag298-B24","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and cancer: a consensus report","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"},{"key":"2026090714312753800_oyag298-B25","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1001\/jama.2008.824","article-title":"Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis","volume":"300","author":"Barone","year":"2008","journal-title":"JAMA"},{"key":"2026090714312753800_oyag298-B26","doi-asserted-by":"publisher","first-page":"g7607","DOI":"10.1136\/bmj.g7607","article-title":"Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies","volume":"350","author":"Tsilidis","year":"2015","journal-title":"BMJ"},{"key":"2026090714312753800_oyag298-B27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12865-018-0261-0","article-title":"Sustained high glucose exposure sensitizes macrophage responses to cytokine stimuli but reduces their phagocytic activity","volume":"19","author":"Pavlou","year":"2018","journal-title":"BMC Immunol"},{"key":"2026090714312753800_oyag298-B28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.6004\/jnccn.2020.7653","article-title":"Understanding the prevalence of prediabetes and diabetes in patients with cancer in clinical practice: a real-world cohort study","volume":"19","author":"Ose","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2026090714312753800_oyag298-B29","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-22-3116","article-title":"Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer","volume":"29","author":"Cortellini","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026090714312753800_oyag298-B30","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"2026090714312753800_oyag298-B31","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/dom.13124","article-title":"Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026090714312753800_oyag298-B32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2174\/1573399812666160613113556","article-title":"Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials","volume":"13","author":"Levine","year":"2017","journal-title":"Curr Diabetes Rev"},{"key":"2026090714312753800_oyag298-B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235811","article-title":"SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives","volume":"14","author":"Dutka","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026090714312753800_oyag298-B34","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B35","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1056\/NEJMc1902837","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Reply","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B36","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B37","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B38","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B39","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B40","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"key":"2026090714312753800_oyag298-B41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"N Engl J Med"},{"key":"2026090714312753800_oyag298-B42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2174\/1574886313666180226103408","article-title":"Risks associated with SGLT2 inhibitors: an overview","volume":"13","author":"Singh","year":"2018","journal-title":"Curr Drug Saf"},{"key":"2026090714312753800_oyag298-B43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","article-title":"The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: CardioOncology state-of-the-art review","volume":"6","author":"Dabour","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026090714312753800_oyag298-B44","doi-asserted-by":"publisher","first-page":"e1322","DOI":"10.34067\/KID.0000000000000219","article-title":"How sweet it is: a perspective on the potential anti-tumor role for SGLT2 inhibitors","volume":"4","author":"Gunasekaran","year":"2023","journal-title":"Kidney360"},{"key":"2026090714312753800_oyag298-B45","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol Metab"},{"key":"2026090714312753800_oyag298-B46","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fonc.2017.00288","article-title":"Identification of clinically approved drugs indacaterol and canagliflozin for repurposing to treat epidermal growth factor tyrosine kinase Inhibitor-Resistant lung cancer","volume":"7","author":"Li","year":"2017","journal-title":"Front Oncol"},{"key":"2026090714312753800_oyag298-B47","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int J Cancer"},{"key":"2026090714312753800_oyag298-B48","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154754","article-title":"Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling","volume":"133","author":"Ding","year":"2023","journal-title":"J Clin Invest"},{"key":"2026090714312753800_oyag298-B49","doi-asserted-by":"publisher","first-page":"113856","DOI":"10.1016\/j.bcp.2020.113856","article-title":"Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin","volume":"175","author":"Zhong","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"2026090714312753800_oyag298-B50","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1002\/1878-0261.13508","article-title":"Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1alpha","volume":"17","author":"Biziotis","year":"2023","journal-title":"Mol Oncol"},{"key":"2026090714312753800_oyag298-B51","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41416-023-02177-2","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival","volume":"128","author":"Luo","year":"2023","journal-title":"Br J Cancer"},{"key":"2026090714312753800_oyag298-B52","doi-asserted-by":"publisher","first-page":"e0274519","DOI":"10.1371\/journal.pone.0274519","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis","volume":"17","author":"Hendryx","year":"2022","journal-title":"PLoS One"},{"key":"2026090714312753800_oyag298-B53","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.195484","article-title":"Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control","volume":"10","author":"Pachimatla","year":"2025","journal-title":"JCI Insight"},{"key":"2026090714312753800_oyag298-B54","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1186\/s12885-025-14733-5","article-title":"Adverse drug events of immune checkpoint inhibitors - a retrospective, descriptive real-world data analysis","volume":"25","author":"Auch","year":"2025","journal-title":"BMC Cancer"},{"key":"2026090714312753800_oyag298-B55","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study","volume":"173","author":"Douros","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026090714312753800_oyag298-B56","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"key":"2026090714312753800_oyag298-B57","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/jgh.16498","article-title":"The impact of sodium-glucose cotransporter-2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer","volume":"39","author":"Chiang","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"2026090714312753800_oyag298-B58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030466","article-title":"Exploring the role of SGLT2 inhibitors in cancer: mechanisms of action and therapeutic opportunities","volume":"17","author":"Pandey","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026090714312753800_oyag298-B59","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s12885-025-13966-8","article-title":"Impact of SGLT2 inhibitors on survival in gastrointestinal cancer patients undergoing chemotherapy and\/or radiotherapy: a real-world data retrospective cohort study","volume":"25","author":"Flausino","year":"2025","journal-title":"BMC Cancer"},{"key":"2026090714312753800_oyag298-B60","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1186\/s12885-025-14453-w","article-title":"Association of sodium-glucose cotransporter-2 inhibitor use and mortality in patients with endometrial cancer: a retrospective cohort study","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"2026090714312753800_oyag298-B61","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40959-023-00199-6","article-title":"Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors","volume":"10","author":"Perelman","year":"2024","journal-title":"Cardiooncology"},{"key":"2026090714312753800_oyag298-B62","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41419-022-04980-w","article-title":"SGLT2 inhibitor activates the STING\/IRF3\/IFN-beta pathway and induces immune infiltration in osteosarcoma","volume":"13","author":"Wu","year":"2022","journal-title":"Cell Death Dis"},{"key":"2026090714312753800_oyag298-B63","doi-asserted-by":"publisher","first-page":"97287","DOI":"10.4239\/wjd.v16.i2.97287","article-title":"Dapagliflozin exerts anti-apoptotic effects by mitigating macrophage polarization via modulation of the phosphoinositide 3-kinase\/protein kinase B signaling pathway","volume":"16","author":"Xiong","year":"2025","journal-title":"World J Diabetes"},{"key":"2026090714312753800_oyag298-B64","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2026090714312753800_oyag298-B65","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/j.1349-7006.2001.tb01175.x","article-title":"SGLT gene expression in primary lung cancers and their metastatic lesions","volume":"92","author":"Ishikawa","year":"2001","journal-title":"Jpn J Cancer Res"},{"key":"2026090714312753800_oyag298-B66","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3892\/ijo.2018.4599","article-title":"MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer","volume":"54","author":"Zhang","year":"2019","journal-title":"Int J Oncol"},{"key":"2026090714312753800_oyag298-B67","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1159\/000536060","article-title":"The clinical relevance of the expression of SGLT2 in lung adenocarcinoma","volume":"102","author":"Iwai","year":"2024","journal-title":"Oncology"},{"key":"2026090714312753800_oyag298-B68","doi-asserted-by":"publisher","first-page":"110821","DOI":"10.1016\/j.biopha.2020.110821","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway","volume":"132","author":"Zhou","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2026090714312753800_oyag298-B69","doi-asserted-by":"publisher","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026090714312753800_oyag298-B70","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00424-020-02448-4","article-title":"SGLT2 and cancer","volume":"472","author":"Wright","year":"2020","journal-title":"Pflugers Arch"},{"key":"2026090714312753800_oyag298-B71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225735","article-title":"Diabetes and cancer: Risk, challenges, management and outcomes","volume":"13","author":"Shahid","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026090714312753800_oyag298-B72","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/cncr.34918","article-title":"Association between diabetes mellitus and reduced efficacy of pembrolizumab in non-small cell lung cancer","volume":"129","author":"Leshem","year":"2023","journal-title":"Cancer"},{"key":"2026090714312753800_oyag298-B73","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag298\/70552619\/oyag298.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag298\/70552619\/oyag298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag298\/70552619\/oyag298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:31:33Z","timestamp":1788805893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag298\/8756827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":73,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag298","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,6]]},"article-number":"oyag298"}}